

The American Journal of Human Genetics, Volume 106

Supplemental Data

**Common Genetic Variants Modulate
the Electrocardiographic Tpeak-to-Tend Interval**

Julia Ramírez, Stefan van Duijvenboden, William J. Young, Michele Orini, Pier D. Lambiase, Patricia B. Munroe, and Andrew Tinker

Supplemental Figures




Figure S1: Exercise stress test (EST-UKB) and Imaging (IMG-UKB) study populations flow diagram.

Additional information can be found in Methods.

FULL-UKB cohort




Figure S2: Full cohort (FULL-UKB) study population flow diagram.






Figure S3: Density plots of resting Tpe intervals in the EST-UKB (blue) and IMAGE-UKB (pink) cohorts.






Figure S4: Manhattan plots of Tpe interval (A), Tpe dynamics during exercise (B) and during recovery (C) in the full cohort analysis.

P values, expressed as $-\log_{10}(P)$, are plotted according to physical genomic locations by chromosome. Lead SNVs are marked by the diamonds. The crosses indicate the P values of these SNVs in the discovery data set. Crosses are encircled for SNVs that formally replicated. Locus names of the novel loci correspond to the nearest annotated gene. The blue horizontal line indicates a P value threshold of 1×10^{-6} , corresponding to the lookup significance threshold. The red horizontal line indicates a P -value threshold of 5×10^{-8} , corresponding to genome-wide significance. Novel loci are highlighted in yellow.






Figure S5: QQ plots for Tpe interval (A), Tpe dynamics during exercise (B) and Tpe dynamics during recovery (C) in the discovery (blue) and full (black) cohorts.


rs10864434




rs603901




rs10789207




rs116532272




rs1050316




rs607484



















rs3770774



rs35450971












Figure S6: Locus Zoom plots for the twenty-eight (ordered by chromosome and base pair position) identified lead SNVs for resting Tpe.


rs607484




rs761499672




rs7373065




rs6801957




rs2080512



rs570620219



rs7373065



rs6801957




Figure S7: Locus Zoom plots for the four loci with secondary signals for resting Tpe.

Left: lead SNV. Right: LZ plot conditioned on the lead SNV.




Figure S8: Locus Zoom plots for the identified loci for Tpe dynamics during exercise.




Figure S9: Locus Zoom plots for the identified locus for Tpe dynamics during recovery.




Figure S10: Locus Zoom plots for the male-specific loci for resting Tpe (males only summary statistics).




Figure S11: Locus Zoom plots for the sex-specific locus for Tpe dynamics during exercise (males only summary statistics).




Figure S12: Locus Zoom plots for the sex-specific loci for Tpe dynamics during recovery (females only summary statistics).





Figure S13: Functional enrichment analysis of resting Tpe loci within DNaseI hypersensitivity spots.

The radial lines show fold enrichment (FE) at eight GWA P -value thresholds. The results are shown for each of 424 cell types which are sorted by tissue, represented along the outer circle of the plot. The font size is proportional to the number of cell types from the tissue. FE values are plotted with different colours with respect to different GWA thresholds. Significant enrichment for a given cell type is denoted along the outer circle of the plot from a GWA P -value threshold.

source	term name	term ID	n. of term genes	n. of query genes	n. of common genes	corrected p-value	ETS2 KCNJ2 EPRI1
cor	ETS2-ETS1 complex	CORUM:2790	2	1	1	3.11e-03	03
cor	ETS2-ERG complex	CORUM:2789	2	1	1	3.11e-03	03
cor	ETS2-SMARCA4-INI1 complex	CORUM:5293	3	1	1	4.66e-03	03
cor	ETS2-FOS-JUN complex	CORUM:2695	3	1	1	4.66e-03	03
rea	Classical Kir channels	R-HSA-1296053	4	2	1	1.51e-02	r
mir	hsa-miR-196b-5p	hsa-miR-196b-5p	151	3	2	1.93e-02	mi mi
mir	hsa-miR-3646	hsa-miR-3646	199	3	2	3.35e-02	mi mi
BP	regulation of skeletal muscle contraction by action potential	GO:0100001	1	2	1	3.77e-02	r
BP	regulation of skeletal muscle contraction via regulation of action potential	GO:0014861	1	2	1	3.77e-02	r

The colors for different evidence codes in the table:



The colors for log scale:




Figure S14: Top biological processes enrichment of candidate genes at Tpe dynamics during exercise loci.

g:profiler GO (gene ontology) term enrichment was performed using the candidate genes for Tpe dynamics during exercise.




Figure S15: Left, adjusted R-squared versus the P -value threshold in the training subset ($N = 247,256$). The optimal cut-off value is the one for which the adjusted R-squared is highest and the P -value is lowest ($P = 0.012$). Right, adjusted R-squared and P -value of the logistic regression in the validation set ($N = 68,563$) using the optimal cut-off value.

Supplemental Tables

Locus	SNV	CH R	BP	E A	MA F	Reporte d P	P in our study	N	β (ms)	PMID
<i>NOS1AP</i>	rs288 0058	1	162014 632	A	-	1.00E- 02	2.90E-03	5,8 90	-0.6	20215 044
	rs465 7139	1	162029 907	T	-	3.00E- 02	9.60E-04	5,8 90	-0.5	20215 044
	rs109 1859 4	1	162030 688	C	-	2.00E- 03	1.40E-03	5,8 90	-0.8	20215 044
	rs104 9436 6	1	162085 685	T	-	2.00E- 02	1.70E-04	5,8 90	-0.6	20215 044
<i>KCNH2</i>	rs180 5123	7	150645 534	A	-	5.00E- 05	4.30E-22	5,8 90	-1.2	20215 044
	rs380 7375	7	150667 210	G	-	1.00E- 03	2.20E-13	5,8 90	0.8	20215 044
<i>KCNE1</i>	rs180 5128	21	358216 80	G	-	2.00E- 01	1.40E-01	589 0	- 1.30 0	20215 044
<i>GRIN2A</i>	rs177 4968 1	16	971393 0	C	0.3 80	2.10E- 07	5.70E-01	187 0	1.45 0	22342 860

KCNJ2	rs72	17	705257	T	0.3	1.10E-	4.20E-148	187	-	22342
	1966		20		80	10		0	1.79	860
	9								0	

Table S1: Previously-reported loci associated with resting Tpe interval.

Abbreviations: SNV: single-nucleotide variation, CHR: Chromosome, BP: Position, based on HG build 19, EA: Effect allele, EAF: Effect allele frequency from discovery data, β : Beta, SE: Standard Error, N: number of participants, P: P-value.

The locus name indicates the gene that is in the closest proximity to the most associated SNV.

Bold indicates replicated in an independent study.

Only one genome-wide significant variant has been previously reported.

Code	Definition
I460	Cardiac arrest with successful resuscitation
I461	Sudden cardiac death, so described
I469	Cardiac arrest, unspecified
I472	Ventricular tachycardia
I490	Ventricular fibrillation and flutter
I499	Cardiac arrhythmia, unspecified

Table S2: ICD-10 codes used in follow-up analysis

Locus	SNV	CHR	BP	EA	EAF	MALES				FEMALES				COMBINED			
						β	SE	P	N	β	SE	P	N	β	SE	P	N
<i>FAAP20</i>	rs2503715	1	2144107	A	0.130	-0.072	0.012	4.20E-10	30532	-0.017	0.011	1.20E-01	34618	-0.043	0.008	6.20E-08	65150
<i>RPL22</i>	rs10864434	1	6262231	A	0.599	-0.052	0.008	1.70E-11	32176	-0.064	0.007	4.60E-18	36482	-0.058	0.005	5.80E-28	68658
<i>SSBP3</i>	rs562408	1	54742618	A	0.433	-0.052	0.008	4.60E-12	32610	-0.046	0.007	1.40E-10	36974	-0.049	0.005	3.20E-21	69584
<i>SGIP1</i>	rs10789207	1	66991346	T	0.785	-0.083	0.009	3.30E-20	33160	-0.026	0.009	2.50E-03	37597	-0.054	0.006	7.50E-18	70757
<i>MEF2D</i>	rs1050316	1	156434703	G	0.346	-0.074	0.008	2.90E-21	33270	-0.052	0.007	3.40E-12	37722	-0.061	0.005	9.40E-30	70993
<i>STRN</i>	rs66993681	2	37118665	C	0.456	0.026	0.008	6.50E-04	33012	0.040	0.007	3.10E-08	37430	0.033	0.005	2.20E-10	70441
<i>SLC8A1</i>	rs35450971	2	40754314	T	0.935	0.034	0.015	2.30E-02	32988	0.085	0.014	5.00E-09	37403	0.062	0.010	3.30E-09	70392
<i>SERTAD2</i>	2:64860029_CTTCAA_C	2	64860029	CTTCAA	0.669	-0.032	0.008	4.70E-05	32360	-0.043	0.008	1.60E-08	36690	-0.037	0.006	1.40E-11	69050
<i>GPR1</i>	rs111520052	2	207101230	G	0.988	0.190	0.034	2.40E-08	33011	0.056	0.033	9.10E-02	37429	0.117	0.024	7.30E-07	70440
<i>SCN5A</i>	rs7373065	3	38710315	T	0.019	-0.126	0.028	5.40E-06	31088	-0.155	0.027	7.90E-09	35248	-0.140	0.019	3.80E-13	66336
<i>NKX2-5</i>	rs6884881	5	172673319	T	0.433	-0.042	0.008	2.60E-08	32465	-0.026	0.007	2.60E-04	36810	-0.034	0.005	6.70E-11	69275
<i>SLC35F1</i>	rs12210810	6	118653204	G	0.945	0.124	0.016	2.60E-14	33432	0.114	0.016	2.00E-13	37906	0.118	0.011	4.60E-26	71338
<i>HEY2</i>	rs10457469	6	126083658	G	0.476	-0.042	0.007	1.90E-08	33350	-0.009	0.007	2.20E-01	37813	-0.024	0.005	1.80E-06	71162
<i>CREB5</i>	7:28413064_CT_C	7	28413064	CT	0.252	0.051	0.009	4.00E-09	32058	0.037	0.008	8.50E-06	36348	0.043	0.006	7.20E-13	68406
<i>KCNH2</i>	rs148064265	7	150626596	G	0.792	-0.068	0.009	1.10E-13	32897	-0.050	0.009	1.70E-08	37299	-0.059	0.006	1.20E-20	70196
<i>AZIN1</i>	rs608236	8	103928940	A	0.433	0.033	0.008	8.50E-06	33025	0.041	0.007	1.10E-08	37445	0.038	0.005	2.80E-13	70471
<i>ZMIZ1</i>	rs1658323	10	80874523	C	0.613	-0.030	0.008	8.30E-05	32152	-0.044	0.007	3.70E-09	36455	-0.038	0.005	2.20E-12	68607
<i>IGF1R</i>	rs4965430	15	99268850	C	0.375	-0.045	0.008	3.70E-09	33110	-0.040	0.007	9.00E-08	37541	-0.042	0.005	2.00E-15	70650
<i>LITAF</i>	rs2080512	16	11692198	G	0.548	-0.026	0.007	4.40E-04	33238	-0.041	0.007	5.80E-09	37686	-0.034	0.005	2.00E-11	70924
<i>LIG3</i>	rs2074518	17	33324382	C	0.535	0.042	0.007	2.40E-08	33432	0.009	0.007	1.90E-01	37906	0.025	0.005	1.60E-06	71338
<i>KCNJ2</i>	rs4399570	17	68479345	G	0.699	0.148	0.008	2.20E-74	33301	0.137	0.008	7.40E-71	37757	0.142	0.006	5.30E-143	71058
<i>PYGB</i>	rs3787080	20	25232604	C	0.741	-0.018	0.009	3.20E-02	33407	-0.051	0.008	1.50E-10	37878	-0.036	0.006	6.50E-10	71285
<i>KCNJ4</i>	rs196064	22	38851392	C	0.631	0.052	0.008	1.40E-11	33203	0.045	0.007	6.50E-10	37646	0.049	0.005	1.30E-20	70848

Table S4A: Sex-stratified analyses for resting Tpe interval.

Lead SNVs at *FAAP20*, *GPR1*, *HEY2* and *LIG3* (indicated in yellow) are male specific loci.

These variants are non-significant ($P > 0.05$) in females only. They were not selected for replication in the discovery analysis, and were non-significant in the combined analyses.

Locus	SNV	CHR	BP	EA	EAF	MALES				FEMALES				COMBINED			
						β	SE	P	N	β	SE	P	N	β	SE	P	N
<i>ETS2</i>	rs2836779	21	40322678	C	0.353	0.061	0.009	1.20E-10	24241	0.007	0.009	4.10E-01	27269	0.032	0.006	5.70E-07	51510

Table S4B: Sex-stratified analyses for Tpe dynamics during exercise.

Lead SNV at *ETS2* (indicated in bold type) is a male specific locus. This variant is non-significant ($P > 0.05$) in females only. It was not selected for replication in the discovery analysis, and was non-significant in the combined analyses.

Abbreviations: SNV: single-nucleotide variant CHR: chromosome, BP: Base pair position, based on HG built 18, EA: effect allele, EAF: effect allele frequency, β : Beta in beats per minute, SE: Standard Error, N: effective number of participants, P: P-value.

Locus	SNV	CHR	BP	EA	EAF	MALES				FEMALES				COMBINED			
						β	SE	P	N	β	SE	P	N	β	SE	P	N
<i>NRXN3</i>	rs77168490	14	80493255	A	0.98	-0.032	0.033	3.26E-01	24172	-0.170	0.031	4.00E-08	27331	-0.102	0.022	5.00E-06	51503
<i>NOL4L</i>	rs565497590	20	31049031	G	0.987	0.025	0.040	5.22E-01	23377	0.214	0.037	1.10E-08	26432	0.119	0.027	8.90E-06	49808

Table S4C: Sex-stratified analyses for Tpe dynamics during recovery.

Lead SNVs at *NRXN3* and *NOL4L* (indicated in yellow) are female specific loci. The variants were not selected for replication from the discovery analyses and were non-significant in the combined analyses.

Abbreviations: SNV: single-nucleotide variant CHR: chromosome, BP: Base pair position, based on HG built 18, EA: effect allele, EAF: effect allele frequency, β : Beta in beats per minute, SE: Standard Error, N: effective number of participants, P: P-value.

Locus	Lead SNP	CHR	BP	eQTL SNV	r2 (Lead SNP-eQTL SNV)	eQTL P-value	Tissue	Transcript	P ₁₂ = 1 x 10 ⁻⁶	
									PP Different signal%	PP common signal%
SSBP3	rs603901	1	54741767	rs590041	0.990	1.48E-10	Heart_Left_Ventricle	SSBP3	6	94
				rs562408	0.990	6.84E-23	Heart_Atrial_Appendage	SSBP3	5	95
SGIP1	rs10789207	1	66991346	rs72677052	0.995	9.43E-26	Heart_Left_Ventricle	SGIP1	7	93
NKX2-5	rs6882776	5	172664163	rs6891790	0.934	2.29E-09	Brain_Cerebellum	NKX2-5	9	91
HEY2	rs10457469	6	126083658	rs3757217	0.990	2.41E-13	Brain_Anterior_cingulate_cortex_BA24	RP11-624M8.1	35	60
				rs1811852	0.990	7.87E-09	Heart_Atrial_Appendage	RP11-624M8.1	37	57
				rs980014	0.979	4.04E-12	Brain_Amygdala	RP11-624M8.1	32	64
MSRA	rs10283145	8	10241411	rs6601450	0.890	4.03E-08	Brain_Hippocampus	RP11-981G7.6	40	59
IGF1R	rs2871974	15	99284074	rs6598541	0.972	5.30E-09	Heart_Left_Ventricle	IGF1R	6	94
LITAF	rs2080512	16	11692198	rs735951	0.992	9.85E-10	Heart_Left_Ventricle	LITAF	4	96
GINS3	rs1424077	16	58462627	rs2042401	0.999	9.62E-17	Brain_Caudate_basal_ganglia	RP11-481J2.2	8	92
				rs4784934	0.993	1.63E-17	Brain_Putamen_basal_ganglia	RP11-481J2.2	12	88
				rs9928581	0.996	3.15E-13	Heart_Atrial_Appendage	NDRG4	11	89
LIG3	rs2074518	17	33324382	rs12945428	0.948	7.04E-24	Heart_Left_Ventricle	LIG3	14	83
						7.30E-18	Brain_Cortex	LIG3	13	85
				rs2339123	0.934	4.07E-10	Brain_Anterior_cingulate_cortex_BA24	LIG3	15	82
						2.92E-12	Brain_Caudate_basal_ganglia	LIG3	17	80
						5.61E-17	Brain_Cerebellar_Hemisphere	LIG3	12	85
				rs1003918	0.992	5.61E-20	Brain_Cerebellum	LIG3	14	84
						3.27E-09	Brain_Hippocampus	LIG3	14	84
				rs978202	0.874	2.93E-11	Brain_Frontal_Cortex_BA9	LIG3	14	84
				rs1088450	0.933	4.01E-11	Brain_Hypothalamus	LIG3	13	85
						8.12E-12	Brain_Nucleus_accumbens_basal_ganglia	LIG3	12	85
		2.09E-09	Brain_Putamen_basal_ganglia	LIG3	13	85				
		1.000	2.09E-09	Brain_Putamen_basal_ganglia	LIG3	13	85			
			8.91E-23	Heart_Atrial_Appendage	LIG3	12	85			

Table S5: Expression quantitative trait locus (eQTL) analysis for resting Tpe interval.

Resting Tpe variants with significant eQTLs and its corresponding genes are indicated. The results from proxy variants, with high LD ($r^2 \geq 0.8$) with the lead variant in the UK Biobank study were included if there was tissue expression data in addition to the lead variant. Results were filtered to those reaching a P value $\leq 5 \times 10^{-8}$. The source was Genotype-Tissue Expression (GTEx) Consortium v7, PubMed ID is 25954001. r^2 : A measure for the linkage disequilibrium between the proxy and lead SNVs; P: P value for the association between the variant and RNA tissue expression.

Columns J and K show the posterior probability of different signal and common signal after applying colocalisation test at a prior probability of 1×10^{-6} that a variant is associated with both traits.

Yellow rows indicate loci with tissue specific eQTLs with a strong colocalisation support.

MeSH term	Name	MeSH first level term	MeSH second level term	Nominal P value	False discovery rate
A07.541	Heart	Cardiovascular System	Heart	1.87E-04	<0.01
A07.541 .560	Heart Ventricles	Cardiovascular System	Heart	2.38E-04	<0.01
A07.541 .358	Heart Atria	Cardiovascular System	Heart	4.45E-04	<0.05

Table S8: DEPICT tissue enrichment across all resting Tpe loci.

Supplemental Methods

Phenotypic and genetic QC

In the EST-UKB cohort, the exercise protocol was adapted according to participants' risk factors. Participants were only included in the study if they were allowed to cycle at 50% or 30% of their maximum workload (no risk to minimum risk). If the heart rate reached the pre-set maximum heart rate level (75% of age-predicted maximum heart rate), the test was stopped. Also, if the participant reported chest pain, felt faint, dizzy or unwell, the test was also stopped (<https://biobank.ctsu.ox.ac.uk/crystal/docs/Cardio.pdf>). We only included participants who terminated the exercise stress test with any discomfort and with a heart rate lower than the pre-set maximum heart rate level.

Individuals were excluded based on existing medical conditions known to affect heart rate (atrial fibrillation, history of myocardial infarction or heart failure, (supra)-ventricular tachycardia, atrioventricular nodal re-entrant tachycardia, second or third degree atrioventricular block, bundle branch block and use of a pacemaker), individuals with a previous cardiovascular event (matching the codes from Supplemental Table 1) and/or individuals on heart rate altering medications (non-dihydropyridine calcium antagonists (Anatomic Therapeutic Chemical (ATC) code C08D, digoxin (ATC code C01AA5), and amiodarone (ATC code C01BD01)). Individuals with an RR interval (inverse of heart rate) change between resting and peak exercise, or between peak exercise and recovery, less than 10 ms or poor quality ECG recording were also excluded.

Individuals with bad genotype quality, provided by UKB, i.e. high missingness or heterozygosity and discordance between the self-reported sex and the sex inferred from the genotypes were excluded¹. We used the k-means function in R as a clustering algorithm, to objectively and statistically select the clusters according to information from PC1 and PC2. The k-means algorithm 'partitions the points into k groups such that the sum of squares from points to the assigned cluster centres is minimised'. Then, we applied k-means separately to

cluster according to each PC1 and PC2, and initially only with $k=4$, for a 4-way clustering, to correspond to the 4 main ethnic clusters within UKB: White, African, Asian and Chinese. We then created an overall clustering, according to the intersections of the PC1-kmeans clustering and the PC2-4means clustering, so that participants were only categorised as 'White' overall, if they were contained in the 'White' cluster for both PCA1 and PC2. Next, we created an overall 'Mixed/Other' cluster, for any participants, whose clustering differed between PC1 and PC2. Finally, we combined the PCA ancestry clusters with the self-reported ethnicity. Individuals were only included if the PCA-clustering results matched the self-reported ancestry. However, we count 'mixed', 'other' and 'missing' as being broad/uncertain self-reported ethnicity, which have now been validated more objectively from the genetic PCA data. We restricted our genetic analyses to individuals with European ancestry.

Genetic analyses

For each trait, we carefully selected covariates based on "a priori" physiological knowledge of the marker, and additional confounding factors were identified using linear regression. Selection of covariates was performed for each trait specifically. The main rationale is that the three traits are physiologically different. For example, resting Tpe quantifies the later stage of ventricular repolarization at rest, which is closely modulated by resting RR interval. In contrast, Tpe response to exercise and recovery quantify the changes in Tpe with exercise and recovery which highly dependent on the corresponding changes in heart rate. We also checked the influence of additional confounding factors, such as smoking, alcohol or diabetes and only included those that were significantly associated.

ECG lead placement during the exercise test

The cardio assessment involved a 3 leads (lead I, II, and III) ECG recording (AM-USB 6.5, Cardiosoft v6.51) at a frequency of 500 Hz. The ECG was recorded using four electrodes placed on the right and left antecubital fossa and wrist (Figure R1) and stored in an xml-file of Cardiosoft (<https://biobank.ctsu.ox.ac.uk/crystal/docs/Cardio.pdf>).

Genetic risk score analyses

Ventricular arrhythmic risk was defined as arrhythmic mortality or admission to hospital with a ventricular arrhythmic diagnosis. The exact International Classification of Diseases, Tenth Revision codes used to define ventricular arrhythmic events are presented in Table S2. Date of death was obtained from death certificates held by the National Health Service (NHS) Information Centre and the NHS Central Register Scotland for participants from England and Wales and participants from Scotland, respectively. Diagnoses were captured using the “Spell and Episode” category from the Hospital Episode Statistics records. This category contains main and secondary diagnoses, coded according to *ICD-10*, made during the hospital inpatient stay. The main diagnoses are those taken to be the main reason for hospital admission, while secondary diagnoses are more often contributory or underlying conditions. We used both the main and secondary diagnoses for recording prevalent and incident risk factors, conditions and events. Date of the event was defined as the date of the first diagnosis.

Variants with minor allele frequency < 0.05 and imputation quality ≤ 0.3 were removed from the calculation. PRSice clumped variants to obtain SNVs in linkage equilibrium ($r^2 < 0.1$) within a 250 kb window. Multiple GRSs were computed at a large number of GWAS *P*-value thresholds ranging from 1×10^{-4} to 0.5 with 5×10^{-5} increments. PRSice then performed a logistic regression analysis between each GRS and ventricular arrhythmic risk, adjusting for age, sex, diabetes, cholesterol, BMI, systolic blood pressure (SBP), the genotyping array and the 10 first genetic principal components. The optimal GRS was then chosen as the one with the smallest *P*-value.

Supplemental References

1. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2017). Genome-wide genetic data on ~500,000 UK Biobank participants. bioRxiv.